Sigma-Aldrich — Corporate Update (January 2005)
17 slides from Sigma-Aldrich's corporate update, Jan 19, 2005
Slide 1: Sigma-Aldrich Corporation: Leveraging Life Science and High Technology For Growth
Exhibit 99.2 Sigma-Aldrich Corporation Leveraging Life Science and High Technology For Growth
Slide 2: Cautionary Statements
Cautionary Statements Our presentation today will include forward looking statements about the Company’s future performance, goals, strategic actions and initiatives and similar expectations, intentions and beliefs, including expectations for sales and earnings growth, cash flow, and debt outstandin
Slide 3: Forecast – Growth
Forecast – Growth Sales ($1.4 billion) Reported >8 % Currency Benefit 5 % Currency Adjusted - Total 3 % - Acquisitions 1 % - Internal 2 % EPS ($3.30 - $3.35/share) Reported 23 - 25 % Currency Benefit 14 - 14 % Currency Adjusted 9 - 11 % Return On Equity >21 % Large Currency Advantage In Sales & EPS
Slide 4: Acquisition Criteria
Acquisition Criteria Sales & Profit Growth >10% Life Science And/Or High Technology Emphasis Build, Not Destroy, Shareholder Value 2% Sales Growth Target
Slide 5: 2004 Acquisitions – Ultrafine and Tetrionics
2004 Acquisitions – Ultrafine and Tetrionics Add 1% Each Year To Sales Growth In Years 1 & 2 Grow 10% Strong Capabilities For Pharmaceutical Industry Strong Development Resources Strategic Technical Competency Capabilities To Serve Pharma Customers
Slide 6: Introducing SAFC
Introducing SAFC Develop & Communicate A New Brand Image Highlight Our Manufacturing Capabilities Scale-Up Custom cGMP Incorporate Our Acquisitions Move From Top 25 To Top 10 FC Company Achieve 12% Growth Goal New Identity For Fine Chemicals
Slide 7: JRH BioSciences - Background
JRH BioSciences - Background Leading Supplier Of Cell Culture Products To Biopharmaceutical Manufacturers Entered Cell Culture Media Market In 1971 Acquired By CSL Limited In 1994 Strong Historical Growth Rates (Sales & Profits) Strong Customer Base, Primary Supplier For Approved Pharmaceutical Prod
Slide 8: JRH BioSciences
JRH BioSciences #2 Overall In Cell Culture Market ($150M), Strong #2 Industrial ($135M), #5 Research ($15M) Locations In U.S., U.K. And Australia High Quality Operations, Facilities Pushing Capacity, Expanding Media Production Second Entrant Into Industrial Market Primary Processor Of Serum Research
Slide 9: Sigma-Aldrich
Sigma-Aldrich #4 Overall In Cell Culture Market ($75M), #5 Industrial ($15M), #3 Research ($60M) Underutilized “State-Of-The-Art” Industrial Facilities Late Entrant To Industrial Market Strong R&D Capabilities Research Business Driven By Reagents, Not Media Limited Penetration, Customers And Pipelin
Slide 10: JRH + Sigma-Aldrich
JRH + Sigma-Aldrich $225 Million #2 Overall To Invitrogen #1 In Industrial Market - $150M #2 In Research Market - $75M Leverage Sigma-Aldrich R&D Leverage Sigma-Aldrich Facilities Share Best Practices Challenging The Cell Culture Market Leader
Slide 11: Proposed Acquisition of JRH BioSciences
Proposed Acquisition of JRH BioSciences Acquisition Cost: $370 million (1) Targeted Close: Dependent on regulatory approval. Expected on or before 3/31. Expected Annual Sales - 2005: $165 million Expected EBITDA - 2005: $37 million (2) Expected Impact On EPS - 2005 (10 months) $(0.10) (3) - 2006 $0.
Slide 12: JRH Acquisition - Synergies
JRH Acquisition Synergies Improvement In COGS By Utilizing New Technologies & Our Facilities Modest SG&A Consolidation Increased Sigma-Aldrich Research Serum Sales Due To Availability Pull-Through Sales Of Our Other Products Synergies Important But Not Deal Determining
Slide 13: JRH Acquisition - Customer Benefits
JRH Acquisition - Customer Benefits Makes Sigma-Aldrich A Leading And Complete Supplier To Biopharmaceutical Customers (Research To Industrial Capabilities) Assured Supply Of Sera At Competitive Prices Enhanced Cell Culture Production Capabilities World Class R&D Capabilities
Slide 14: JRH Acquisition – Shareholder Benefits
JRH Acquisition – Shareholder Benefits Investment In Future Growth Acquisition Of A Quality Company That Is A Leader In Its Field Increased Sales Due To Serum Availability Pull Through Sales Of Other Products Industrial Market Growth Exceeds Research Market Accretive to EPS After Year 1 Adds To Cash
Slide 15: 2005 Projections With JRH BioSciences
2005 Projections With JRH BioSciences Growth Sales ($1.650 - 1.700 bil) Reported 18 - 21 % Currency Benefit 6 - 6 % Currency Adjusted 12 - 15 % EPS ($3.45 - 3.55) 5 - 8 % Return On Equity 20 % Key Assumptions 12/31/04 FX Rates Effective Tax Rate Of 29% Repurchase Of 1.5 Million Shares JRH Closing On
Slide 16: 2005 Debt Projections
2005 Debt Projections ($’s In Millions) WithoutAcquisition With JRH Projected Debt @ 12/31/05 - Private Placement Due Sept. 2010 $100 $100 - Private Placement Due Nov. 2006 75 75 - New 3 Year Term Debt Due Feb. 2008 — 150 - Short-Term Debt 95 200 - Other 3 3 TOTAL $273 $528 Debt To Total Capitalizat
Slide 17: Sigma-Aldrich Corporation
Sigma-Aldrich Corporation Future Based On Leveraging Life Science and High Technology For Growth